{"prompt": "['MC1752', '17', 'Active Monitoring Phase', 'C4-C10', 'End of', '6 Mo after', 'EOS', '<70', 'Screening', '(D43, D57,', 'Treatment', 'registratio', '9 Mo after', '(12 Mo after', 'days', '(28 days', 'D71, D85,', '(30 days', 'n', 'registration', 'registration)', 'Tests and', 'prior', 'prior to', 'C1', 'C2', 'C3', 'D99, D113,', 'after last', '(Clinical', '(Clinical', '(Clinical', 'procedures', 'to reg', 'reg)', '(D1)', '(D15)', '(D29)', 'D127)', 'dose)', 'Follow-up)', 'Follow-up)', 'Follow-up)', 'Window', '3 days', '3 days', '3 days', '3 days', '14 days', '14 days', '14 days', 'Blood-', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'chemistries6', 'X', 'Free T4 and', 'X', 'X7', 'X\u00b9', 'X7', 'TSH', 'Urine cytology', 'X', 'X', 'X', 'X', 'Urodynamic', 'X5', 'XR', 'study', 'Bladder Biopsy', 'X', 'X', 'Cystoscopy', 'X', 'X', 'X', 'X', 'QOL forms\u00b9', 'X', 'X', 'X', 'Optional', 'Research', 'specimens', 'per IRB 16-', '0052609', 'Optional', 'Archived', 'research', 'tissue', 'specimens', '10,R', 'Cycle = 14 days All tests and procedures are clinically indicated, unless noted with an R to indicate funding by research', '1. For women of childbearing potential only. Serum must be performed <14 days prior to registration', '2. CBC with differential', '3.', 'Abdomen, pelvis, chest CT/MRI to be done at C7(Day 85) +/- 7 days', '4. Adverse event/Toxicity notation to be done WEEKLY during radiation treatment', '5. Uroflow/post void residual; not required to be done prior to registration; however, if done then data will be collected.', '6.', 'Blood chemistries: Comprehensive Metabolic Panel (CMP) {Albumin, Bilirubin(total) Calcium, Carbon dioxide', 'Protocol Version Date: 21JUN2018']['MC1752', '18', '(bicarbonate), Chloride, Creatinine, Glucose, Phosphatase alkaline, Potassium, Protein (total), Sodium, Transferase aspartate', 'amino(AST) (SGOT), Transferese alanine amino (ALT) (SGPT), Urea nitrogen (BUN} and Mg prior to each avelumab dose,', 'at end of study visit, and 30 days post-treatment safety follow-up', '7. Free T4 and TSH at least every 8 weeks during treatment (Collect at same time as treatment related labs). Also collect at end', 'of study or 30 days post-treatment safety follow-up (if not performed in the previous 8 weeks)', '8. With contrast preferred; however if treating Provider determines that contrast is contraindicated then contrast can be omitted.', '9. NOTE: Participants sign a separate consent for IRB 16-005260', '10. Archived tissue per section 17.0', '11. EORTC QLQ-C30 (Appendix II) and EORTC QLQ-BLM30 (Appendix III). Booklets are to be used', 'for', 'this', 'study.', 'R Research funded (see Section 19.0)', '4.1', 'Survival Follow-up', 'This study does not involve survival follow-up. Patients are considered off study 12 months after registration.', 'Protocol Version Date: 21JUN2018']\n\n###\n\n", "completion": "END"}